Ocugen (FRA:2H51) Other Long-Term Liabilities

: €0.48 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Ocugen's other long-term liabilities for the quarter that ended in Dec. 2023 was €0.48 Mil.

Ocugen's quarterly other long-term liabilities increased from Jun. 2023 (€0.42 Mil) to Sep. 2023 (€0.47 Mil) and increased from Sep. 2023 (€0.47 Mil) to Dec. 2023 (€0.48 Mil).

Ocugen's annual other long-term liabilities increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.23 Mil) and increased from Dec. 2022 (€0.23 Mil) to Dec. 2023 (€0.48 Mil).

Ocugen Other Long-Term Liabilities Historical Data

The historical data trend for Ocugen's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Ocugen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Long-Term Liabilities																-	-	-	-	-

Ocugen Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Ocugen Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Ocugen's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocugen (FRA:2H51) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (FRA:2H51) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

OCGN:USA OCGN:Mexico

Address

11 Great Valley Parkway, Malvern, PA, USA, 19355

Website

https://www.ocugen.com

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.

Ocugen (FRA:2H51) Headlines

No Headlines